Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses by Anthoney, DA et al.
Anthoney et al. BMC Cancer 2012, 12:536
http://www.biomedcentral.com/1471-2407/12/536RESEARCH ARTICLE Open AccessPhase I study of TP300 in patients with advanced
solid tumors with pharmacokinetic,
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Tomohisa Saito4, Masaichi Abe4, Keith Jones5, Masanori Miwa4, Christopher Twelves1* and TRJ Evans2Abstract
Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting
toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076,
and active metabolite, TP3011.
Methods: Eligible patients with refractory advanced solid tumors, adequate performance status, haematologic,
renal, and hepatic function. TP300 was given as a 1-hour i.v. infusion 3-weekly and pharmacokinetic (PK) profiles of
TP300, TP3076 and TP3011 were analysed. Polymorphisms in CYP2D6, AOX1 and UGT1A1 were studied and DNA
strand-breaks measured in peripheral blood mononuclear cells (PBMCs).
Results: 32 patients received TP300 at 1, 2, 4, 6, 8, 10, 12 mg/m2. MTD was 10 mg/m2; DLTs at 12 (2/4 patients) and
10 mg/m2 (3/12) included thrombocytopenia and febrile neutropenia; diarrhoea was uncommon. Six patients (five
had received irinotecan), had stable disease for 1.5-5 months. TP3076 showed dose proportionality in AUC and Cmax
from 1–10 mg/m2. Genetic polymorphisms had no apparent influence on exposure. DNA strand-breaks were
detected after TP300 infusion.
Conclusions: TP300 had predictable hematologic toxicity, and diarrhoea was uncommon. AUC at MTD is
substantially greater than for SN38. TP3076 and TP3011 are equi-potent with SN38, suggesting a PK advantage.
Trial registration: EU-CTR2006-001345-33
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inhibitorBackground
Inhibition of topoisomerase-I (Topo-1) is a clinical-
ly proven treatment strategy for many cancers [1]. Iri-
notecan hydrochloride is the most widely used
topoisomerase-I inhibitor, approved for the treatment of
patients with colorectal cancer previously treated with 5-
fluorouracil [2]. It also has activity against a wide range
of other cancers (eg. glioma, gastric, non small cell lung
and pancreatic cancers), either as a single agent or in
combination [3-6]. Irinotecan has, however, a number of
properties that limit its usefulness. It is metabolized* Correspondence: c.j.twelves@leeds.ac.uk
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reproduction in any medium, provided the orenzymatically by carboxylesterase 2 (CES2), predom-
inantly within the liver, to SN-38 (a significantly more
potent Topo-1 inhibitor). This conversion shows con-
siderable inter-individual variability, resulting in a wide
range of systemic SN-38 exposure for a given dose that
may influence the efficacy and toxicity of irinotecan.
Clinically, the use of irinotecan is limited by diarrhoea
and neutropenia with potential impact on dose intensity
as well as patient acceptability; low activity of the SN-38
metabolising enzyme UGT1A1 is associated with a
greater risk of diarrhoea and myelosuppression [6], and
in 2005 the US FDA recommended irinotecan dosing be
modified in patients carrying the UGT1A1*28 poly-
morphism [2,7]. The development of Topo-1 inhibitors
not subject to such pharmacogenomic variability might,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agents.
TP300 (glycine,glycyl-N-methyl-,(9S)-9-ethyl-9,10,13,15-
tetrahydro-10,13-dioxo-1-pentyl-1H,12H-pyrano[3'',4'':60,7 0]
indolizino[20,10:5,6]pyrido[4,3,2-de]quinazolin-9-yl ester,
hydro-chloride) has been developed as a water soluble pro-
drug of theTopo-1 inhibitor TP3076, and its active metabol-
ite, TP3011, both of which are equipotent to SN38 in terms
of Topo-1 inhibition (Figure 1) [8]. TP300 has activity at
nanomolar concentrations across a range of tumour types
in vitro and, unlike SN38, appears active in tumours over-
expressing the breast cancer resistance protein [BCRP] [8].
In man, TP300 is converted non-enzymatically to TP3076,
then metabolized to TP3011 by aldehyde oxidase 1 (AOX1;
Figure 1) [9]. TP3011 and TP3076 are equipotent as Topo-1
inhibitors, with IC50 in the sub-nanomolar range HCT-116
colorectal cancer cells in vitro [10]. Importantly, TP3076
lacks a phenolic-OHgroup in its structure such that it cannot
be glucuronidated in the same way as irinotecan and also
should not be influenced to any great extent by polymorph-
isms in the UGT1A1 gene. There should, therefore, be less
inter-individual variation in activation and toxicity with
TP300 thanwith irinotecan; specifically, it would be expected
that severe diarrhoea should not be an issue.
The primary objectives of this Phase I first in man
study of TP300 in patients with advanced solid tumours,
were to establish the maximum tolerated dose (MTD),
dose-limiting toxicity (DLT), and recommended Phase II
dose of TP300 but also incorporated pharmacokinetic,
pharmacogenomic and pharmacodynamic evaluation.
Methods
Patients and eligibility criteria
This was a Phase I, open-label, non-randomized, two
center dose-escalation study, conducted in accordance
with the ICH GCP and approved by each participating
institution’s Research Ethics Committee. All patients
provided written informed consent.
Eligible patients were ≥ 18 years old, with histologically
or cytological confirmed advanced solid malignancies
who were refractory to standard therapies or forN N
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Figure 1 The fate of TP300, active form (TP3076) and its metabolite (Twhom there was no effective standard therapy, and with
Eastern Cooperative Oncology Group (ECOG) perform-
ance status ≤ 2. Further criteria for inclusion included
adequate bone marrow function (neutrophil count ≥ 1.5
x109, platelet count ≥ 1 x109, and haemoglobin≥10.0 g/dL)
and adequate hepatic (serum bilirubin ≤ 1.5 x upper
limit of normal [ULN], alanine amino transferase (ALT)
and aspartate amino transferase (AST) ≤ 2.0 x ULN) and
renal (serum creatinine ≤ 1.5 x ULN) function.
Standard Phase I trial exclusion criteria included ex-
posure to prior cytotoxic chemotherapy, extended field
radiotherapy or surgery within 4–6 weeks before the
start of the study; presence of severe concomitant med-
ical illness; and the presence of symptomatic brain me-
tastases. A history of severe or life-threatening drug
allergy or hypersensitivity to camptothecin derivatives
and diarrhoea (excess of 2–3 stools/day above normal
frequency within 2 weeks prior to the start of the study)
were additional exclusion criteria.
Treatment and dose escalation
TP300 was given as a 1-hour intravenous (i.v.) infusion,
by peripheral venous catheter, every 3 weeks.
TP300 sterile concentrate solution for intravenous in-
fusion was supplied in vials containing 5 mL solution at
a concentration of 4 mg/mL of the free base active ingre-
dient. Other ingredients were glycine, sodium chloride,
hydrochloric acid and water for injection. Before infu-
sion, each vial was diluted in 0.9% sodium chloride for
infusion. Infusion bags used for the different dosages
were < 2.0 mg/m2 TP300 50 mL and at other dosages
100 mL. pH was less than 2, so care was taken with the
site of administration, looking for any evidence of local
irritation.
The starting dose of 1 mg/m2 was derived from single
and repeat dose toxicity studies and represented one
sixth of 0.3 mg/kg (6 mg/m2), a dose tolerated without
evidence of serious, irreversible or life-threatening tox-
icity in the most sensitive of the two species tested.
Doses were doubled in subsequent cohorts until grade
≥2 toxicity was observed, whereupon a modifiedN
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hort the first patient was required to complete 1 cycle
before subsequent patients were entered. Intra-patient
dose-escalation was not allowed.
Three patients were planned per cohort, with up to 3
added if dose limiting toxicity (DLT) was observed in
the initial group, and an expanded cohort at the max-
imum tolerated dose (MTD). The MTD was the dose
level below that at which ≥ 2 out of 3–6 patients experi-
enced a DLT. Radiologic assessment of disease was per-
formed every 2 cycles. Patients could remain on
treatment if there was evidence of clinical benefit but
were withdrawn from the study upon clinical or radio-
logic progression, unacceptable toxicity or withdrawal
of consent.
Evaluation of toxicity
Toxicity was assessed weekly and graded using the Na-
tional Cancer Institute Common Toxicity Criteria
(CTCAE) version 3.0. DLT was defined as the occurrence
of any of the following adverse events: grade 4
thrombocytopenia; febrile neutropenia or grade 4 neu-
tropenia > 5 days duration; grade 4 diarrhoea not
reduced to grade 1 within 2 days of appropriate therapy;
other gastro-intestinal toxicities (e.g. vomiting, nausea,
stomatitis) ≥ grade 3 and not reduced to grade 1 within
2 days of appropriate therapy; any other non-
haematologic toxicities ≥ grade 3 (excluding alopecia).
Pharmacokinetic assessments
Venous blood (3 mL) was taken into sodium heparin
tubes containing 30 μL of 46% citric acid, centrifuged
1500g at 4°C for 10 min and 1 mol/L hydrochloric acid
was added (1:10) to plasma from each subject at 10 time
points during cycle 1 (pre dose, then 1, 1.25, 1.5, 2, 3, 5,
8, 24, 48 hours after the start of administration) and
stored at −70°C. Samples were processed by extraction of
protein using addition of organic solvent containing in-
ternal standards and assayed by LC-MS/MS with a
robust, sensitive and validated method for the simultan-
eous determination of a novel topoisomerase 1 inhibitor
CH0793076 (TP3076), the prodrug CH4556300 (TP300),
and the active metabolite CH0793011 (TP3011) [9]. All
plasma had been acidified during collection to avoid the
pH-based degradation of TP300 and to shift the equilib-
ria of TP3076 and TP3011 between the lactone and carb-
oxylate forms towards the lactone forms. After the
plasma proteins were precipitated with methanol:aceto-
nitrile:HCl 1M (50:50:1, v:v:v) containing stable isotopic
internal standards, the analytes were trapped on an
Xterra MS C18 column (10×2.1 mm i.d., 5 μm) and
separated on a Gemini C18 column (50×2.0 mm i.d.,
5 μm) using column-switching liquid chromatography.
Electrospray ionization in the positive-ion mode andmultiple reaction monitoring were used to quantify the
analytes with transitions m/z 587.2>441.2 for TP300,
459.1>415.2 for 3076, and 475.1>361.1 for 3011. The
inter- and intra-day precisions were below 12%, and the
accuracy was between −16% and 16% at the lower limit
of quantitation (LLOQ) and between −11% and 14% at
the other quality controls. The LLOQs of TP300,
TP3076, and TP3011 were 0.8, 0.04, and 0.04 ng/mL,
respectively.
Pharmacokinetic parameters derived from plasma
concentration-time data of TP3076 or TP3011 by non-
compartmental methods using WinNonlin (version 5.1;
Pharsight Corp), included maximal plasma concentration
(Cmax) and time of Cmax (Tmax), apparent plasma elimin-
ation half-life (t1/2), and the area under the curve (AUC).
The urinary excretion ratio (fe) of TP3076 and TP3011
was calculated from the urinary concentration and vol-
ume up to 48 hours after administration, and the admin-
istration dose. The linearity of Cmax and AUC was
determined with linear regression, analysis of variance
and power model analysis. The sum of the AUCs of
TP3076 and TP3011 was plotted against percentage (%)
fall in nadir neutrophil count to explore the relationship
between exposure and myelosuppression as a measure of
anti-proliferative effect and a sigmoid Emax model fitted
to the data:
Effect ¼ AUCTP3076 þ AUCTP3011ð Þ
γ
AUCTP3076 þ AUCTP3011ð Þγ þ EAUC50γ
where γ is the Hill equation constant and EAUC50 is the
AUC associated with 50% of the maximal effect.
Pharmacogenomic analysis
Blood samples for pharmacogenomic analysis were col-
lected and all samples anonymised for subsequent stor-
age, assay and analysis. The impact on Cmax and AUC of
genetic polymorphisms of CYP2D6, which is assumed to
make some contribution to the hydroxylation of
TP3076, but not TP3011, AOX1, which metabolises
TP3076 to TP3011, and UGT1A1, which metabolises
SN-38 to its glucuronide, but is not believed to influence
TP300 metabolism were explored. The analysis was per-
formed with the invader method or polymerase chain re-
action (PCR)-invader method for single nucleotide
polymorphisms (SNPs) of CYP2D6 and UGT1A1 *28
and with the long-PCR method for deletion of CYP2D6
and UGT1A1 gene. AOX1 SNPs were analysed by a
direct sequencing method. Genomic DNAs were
extracted from frozen peripheral blood of 31 subjects
using an automated DNA extractor BioRobotMDx and
commercial DNA purification kits (Qiagen). Quality and
quantity of the DNAs were checked by the measurement
of absorbencies at 260 nm and 280 nm. Primers were
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1 gene (NCBI accession No. NM_001159) including
some intronic flanking regions. The specificity of PCR
conditions was confirmed by the agarose gel electrophor-
esis. Amplicons were prepared twice for every exons.
The amplicons were subsequently treated with ExoSAP-
IT (GE Healthcare) followed by the reactions with a
cycle sequencing kit (BigDye Terminator v3.1, Applied
Biosystems). The fragments obtained were purified using
X-Terninator purification kit (Applied Biosystems) and
analysed on an automated DNA sequencer (3730xl DNA
Analyzer, Applied Biosystems). The resulted sequences
were compared against the reference sequence using the
variant reporter software (Applied Biosystems).Pharmacodynamic analysis
Analysis of the ability of TP300 to induce DNA strand
breaks was performed on peripheral blood mononuclear
cells (PBMCs), pre-dose, 1, 3 and 24 hours post cycle 1.
A validated single cell gel electrophoresis (comet) assay
was used to assess DNA single-strand breaks [11]. An
average of 50 PBMC cells/time-point were analysed and
the tail moment (TM) calculated, as the product of the
percentage of DNA in the comet tail and the distance
between head and tail distributions; higher TM values re-
flect greater DNA strand breakage. Statistical analyses
were not performed due to the limited number of sub-
jects/samples per cohort.Table 1 Demographic and baseline characteristics
Demographic data
Variable
Age (years)
Number of regimens of previous chemotherapy
Sex
ECOG performance status
Site of primary cancer
Continuous data: Minimum-Maximum (Median).Results
Patient characteristics
Thirty two patients were recruited between September
2006 and October 2008. TP300 doses were 1, 2, 4, 6, 8,
10, 12 mg/m2. Of the 32 patients, 21 received two cycles
of TP300, five received three to seven cycles. Patient
characteristics are shown in Table 1.
Toxicity
Toxicity from TP300 was predominantly haematologic
with neutropenia the DLT. Minimal toxicity was
observed at doses up to and including 8 mg/m2. Two/
four patients dosed at 12 mg/m2 experienced DLT: grade
4 febrile neutropenia (5 days duration) and grade 4 neu-
tropenia (15 days). As 8 mg/m2 had been well tolerated,
the intermediate dose of 10 mg/m2 was explored in 12
patients, and 3 experienced a DLT: grade 3 febrile neu-
tropenia (9 days); grade 4 neutropenic sepsis (8 days)
with concomitant grade 4 thrombocytopenia (7 days);
and grade 4 uncomplicated neutropenia (7 days). No pa-
tient received growth factor support during neutropenic
episodes. Six patients, who had experienced DLT, on
subsequent recovery, continued TP300 dosed at the pre-
vious dose.
Non-haematologic toxicity was generally mild and
self-limiting and no patient experienced cholinergic
effects. A summary of grade ≥ 3 toxicities is shown in
Table 2. Specifically, only 8 patients developed diarrhoea,
grade 2 at worst and arising on average 9.5 days (range 1Total
N=32
31-72 (58.0)
1-4 (2)
Male 20 (62%)
Female 12 (38%)
0 8 (25%)
1 20 (63%)
2 4 (13%)
Breast 1 (3%)
Colon 6 (19%)
Lung 1 (3%)
Pancreas 2 (6%)
Pleura 1 (3%)
Rectum 7 (22%)
Soft tissue 2 (6%)
Stomach 4 (13%)
Other 8 (25%)
Table 2 Summary of suspected treatment related adverse events
Summary of adverse events occurred within cycle 1
All grade
N = 32
No. (%)
Grade 3
N = 32
No. (%)
Diarrhea 8 ( 25) 0 (0)
Nausea 13 ( 41) 0 (0)
Vomitting 9 ( 28) 0 (0)
Anaemia 6 ( 19) 2 ( 6)
Neutropenia 6 ( 19) 6 ( 19)
Leukopenia 3 ( 9) 3 ( 9)
Thrombocytopenia 3 ( 9) 3 ( 9)
Febrile neutropenia 2 ( 6) 2 ( 6)
Lethargy 12 ( 38) 4 ( 13)
Syncope 1 ( 3) 1 ( 3)
Chills 2 ( 6) 1 ( 3)
Hepatorenal failure 1 ( 3) 1 ( 3)
Neutropenic sepsis 1 ( 3) 1 ( 3)
Back pain 1 ( 3) 1 ( 3)
Dyspnoea 1 ( 3) 1 ( 3)
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concomitant dose-limiting myelosupression. There were
no other ≥ grade 3 gastrointestinal toxicities.
TP300 was discontinued due to toxicity in 4 patients,
but there were no treatment-related deaths. TP300 dose
was modified at cycle 2 in 4 patients; from 12 to 8 mg/m2
1 patient, from 10 to 8 mg/m2 2 patients, and from 6 to 4
mg/m2 1 patient. Five cycles were delayed in 3 patients
due to disease-related morbidity (3), gastroenteritis (1),
and anaemia (1).
Antitumour activity
There were no complete or partial responses as deter-
mined by RECIST. However, six patients had stable dis-
ease as their best response (1 each at 4, 8 and 12 mg/m2
and 3 at 10 mg/m2) lasting between 1.5-5 months of
whom five had previously been treated with irinotecan.
One patient with metastatic gastric adenocarcinoma (4
mg/m2) had a clinically significant improvement of ma-
lignant ascites and stabilization of established peritoneal
metastases over 7 cycles.
Pharmacokinetic analyses
The plasma concentration-time profiles of TP3076 and
TP3011 are shown in Figure 2 and a summary of pharmaco-
kinetic parameters in Table 3. TP300 rapidly disappeared
and all measured concentrations 1.5 h after dose were below
the limit of the quantification. Plasma TP300 concentration
1 h after administration was obtained only at the doses of 2,
8, 10 and 12 mg/m2 and the mean concentration was 3.48,2.34, 7.37 and 18.4 ng/mL, respectively. Meanwhile, Tmax for
TP3076 was at the end of infusion (1 hour) and that of the
metabolite TP3011 was at 3–5 hours. Urinary excretion
ratios of TP3076 and TP3011 were low and represented at
most 6% at the highest dose. The Cmax and AUC of TP3076
and TP3011 increased proportionately up to 10 mg/m2
TP300 (Figure 3) and inter-patient variability was small.
Pharmacokinetic analyses revealed a strong relationship
between exposure to the metabolites of TP300 and falls in
the neutrophil count. Figure 4 shows a scatter plot of 1-
nadir/pre-observation neutrophils in cycle 1 against the total
AUC of TP3076 plus TP3011 with a sigmoid Emax curve fit-
ted. EAUC50 was 1.31 and γ was 0.862. The fall in neutrophil
count was related to total AUC of TP3076 plus TP3011. All
5 patients with haematologic DLT were amongst the 9 who
had a total TP3076 and TP3011 AUC of approximately 4.5
μmol*h/L or more.
Pharmacogenetic analyses
The Cmax and AUC of TP3076 or TP3011 were categor-
ized with respect to CYP2D6, AOX1 and UGT1A1 geno-
types and box plots were prepared (Figure 5). The (TA)
6/6 (n=16), (TA)6/7 (n=10) and (TA)7/7 (n=5) genotypes
of UGT1A1*28 were identified, but there was no appar-
ent significant difference in exposure among these geno-
types. A/A (n=23) and A/G (n=8) genotypes of AOX1
(c3404A > G) were observed; again, there was no appar-
ent significant difference of exposure among these geno-
types. The CYP2D6 phenotype was divided into
extensive (neither CYP2D6 *3 or *4 mutation; n=13),
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Figure 2 Time-plasma concentration profile of TP300, TP3076
and TP3011. A: The plasma concentration profile of TP300. B: The
plasma concentration profile of TP3076. C:The plasma concentration
profile of TP3076. Square:1 mg/m2, Circle:2 mg/m2, Triangle (point
up):4 mg/m2, Cross:6 mg/m2, X:8 mg/m2, Diamond:10 mg/m2,
Triangle (point down):12 mg/m2.
Anthoney et al. BMC Cancer 2012, 12:536 Page 6 of 10
http://www.biomedcentral.com/1471-2407/12/536intermediate (heterozygous *3 or *4 mutation; n=14) and
poor (homozygous *3 or *4 mutation; n=4) metabolizers
[12,13]. There appeared to be a slight reduction in ex-
posure to TP3076 in the extensive metabolisers, with a
corresponding slight decrease in TP3011 exposure.
Pharmacodynamic analyses
Full comet profiles (pre-dose, 1, 3, 24 hours post first
dose) were available in 29 patients. The overall pre-treatment study mean tail moment (TM) across all doses
was 0.69; compared to 1.65 at 1 hour, indicating approxi-
mately 2-fold increase of DNA strand breaks. Although
there was no clear relationship between TP300 dose and
the extent of strand breaks, the highest two doses (10
and 12 mg/m2) were associated with greater DNA dam-
age (Figure 6). The mean TM was generally lower at 3
hours compared with 1 hour, with little further change at
24 hours.
Discussion
This Phase I study demonstrates that the novel
topoisomerase-I inhibitor TP300 has a good tolerability
profile, and achieved several key aims that were central
to its design. More specifically, as an inactive pro-drug it
is rapidly converted to the active form TP3076, then
metabolized to TP3011 in a consistent manner, not influ-
enced by genetic polymorphisms. The likelihood of un-
predictable, severe diarrhoea is diminished by the
absence of the variable glucuronidation associated with
SN-38. As predicted, TP300 does not cause acute diar-
rhea, which results from acetylcholine esterase inhibition
[8]. Target interaction with the induction of DNA strand
breaks was shown.
The main toxicity of TP300 was haematologic with
neutropenia and, to a lesser extent thrombocytopenia,
being dose limiting. In general, neutropenia was short
lived; no patient received G-CSF support (acutely/
prophylactically). At the maximum achievable dose, 12
mg/m2, grade 4 haematologic toxicity was observed (2/4
patients). As there had been no grade 3/4 haematologic
toxicity at 8 mg/m2, 10 mg/m2 was explored in 12
patients. At 10 mg/m2 3 patients experienced grade 4
haematologic toxicity and although generally well toler-
ated, there was a risk of short lived but significant neu-
tropenia and thrombocytopenia. The recommended
Phase II starting dose is 8 mg/m2, escalating to 10 mg/
m2 on subsequent cycles, if initial treatment is well
tolerated.
In marked contrast to irinotecan, gastrointestinal toxicity
was in general mild, with no diarrhoea greater than grade 2.
Likewise, there were no acute cholinergic reactions with its
associated early diarrhoea [8,14,15]. This validates the design
of TP300 as acute cholinergic reactions are associated with
the 4-piperidinopiperidine moiety at the 10-position of irino-
tecan [16], not found in TP300.
Pharmacokinetic data confirm that TP300 is rapidly con-
verted in plasma to the active metabolite TP3076, supporting
a pH dependent chemical change occurring at physiological
conditions. Hepatic aldehyde oxidase converts TP3076 to a
further metabolite TP3011, which reaches maximum con-
centrations 3–5 hours after the end of infusion, and also has
potent topoisomerase-I inhibitory activity. Pharmacogenetic
analysis of aldehyde oxidase genotype, which was reported
Table 3 Summary of pharmacokinetic parameters of TP3076 and TP3011
TP3076 Dose (mg/m2) 1 2 4 6 8 10 12
Parameter N 3 3 3 3 3 12 4
Cmax (ng/mL) Mean 26.1 76.9 152 185 196 326 688
S.D. 7.46 3.65 56.4 29.8 56.1 99.4 209
AUC (ng*h/mL) Mean 52.9 209 335 405 451 1000 2450
S.D. 8.26 103 130 120 87.8 476 1330
tmax (h) Mean 1.26 0.966 1.02 1.01 1.10 1.07 0.983
S.D. 0.242 0.0289 0.168 0.0587 0.137 0.111 0.0236
t1/2 (h) Mean 2.35 3.73 7.04 5.97 6.22 5.14 4.93
S.D. 0.990 1.33 3.30 0.951 0.979 1.08 0.535
fe (%) Mean 2.45 2.87 1.31 1.78 1.71 3.09 6.33
S.D. 1.14 0.769 0.830 1.46 1.02 2.52 1.20
TP3011 Dose (mg/m2) 1 2 4 6 8 10 12
Parameter N 3 3 3 3 3 12 4
Cmax (ng/mL) Mean 3.13 9.12 38.3 32.5 34.2 89.5 150
S.D. 1.97 4.93 23.5 16.4 12.0 82.3 80.5
AUC (ng*h/mL) Mean 35.1 94.0 284 379 427 1300 2030
S.D. 24.8 77.2 140 259 114 1640 1590
tmax (h) Mean 3.21 2.66 2.58 3.84 3.11 4.59 5.27
S.D. 1.74 0.601 0.811 1.98 1.83 1.62 2.06
t1/2 (h) Mean 6.92 6.56 7.18 10.0 9.52 8.60 7.41
S.D. 3.15 2.66 2.87 2.87 1.72 1.95 1.13
fe (%) Mean 0.792 0.739 0.796 0.593 0.594 1.10 1.99
S.D. 0.676 0.279 0.633 0.492 0.385 0.987 1.59
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any effect on exposure to either TP3076 or TP3011. Glucur-
onidated TP3076 was not detected, reflecting UGT1A1 vari-
ant status had no influence on exposure to either TP3076 or
TP3011. These pharmacokinetic data reflect the design strat-
egy. There may be a small effect of CYP2D6 metaboliser
genotype on exposure to TP3076, and consequently
TP3011. The AUC of TP3076 and TP3011 were linearly
proportional up to 10 mg/m2, but at 12 mg/m2 there was
greater inter-patient variability.
There was a strong relationship between the combined
total AUC of TP3076 and TP3011 and the nadir neutro-
phil count, with an AUC of ≥ 4.5 hr.μmol/L generally
correlating with a more significant neutrophil fall, specif-
ically 5 of 8 patients (62.5%) with an AUC above this
value experienced dose limiting neutropenia. With a 3-
weekly dosing regimen of irinotecan, at 350 mg/m2,
DLTs occur at AUCs of the active component, SN-38, of
1.5 μmol.h/L [18], SN-38 AUC is variable, influenced by
UGT polymorphism. The active components of TP300
(TP3076 and TP3011) are equipotent to SN38 as Topo-1
inhibitors [8] and are not influenced by UGT poly-
morphisms. This means, therefore, that the combinedAUC of the active components of TP300 is approxi-
mately 3-fold greater than that of SN-38, with reduced
inter-individual variability indicating greater predictabil-
ity of toxicity.
The comet assay demonstrated a consistent pattern
with increased PBMC DNA strand breaks 1 hour after
the end of infusion, generally falling by 3 hours. A simi-
lar pattern with modest and transient appearance of
strand breaks was seen with temozolomide [19]. Al-
though there were more strand breaks at higher TP300
doses, this was less clear than the relationship between
pharmacokinetic exposure and neutrophil fall. However
the comet data give valuable proof-of-principle that
TP300 is damaging DNA, but the semi-quantitative na-
ture does not allow a biologically optimal dose of TP300
to be identified. Without published data on DNA strand
breaks in patients treated with irinotecan, a direct com-
parison with TP300 cannot be made. A more relevant
pharmacodynamic endpoint in future may be to measure
DNA strand breaks in tumour cells.
There were no objective tumour responses. However,
one patient with metastatic gastric adenocarcinoma, bi-
lateral ovarian metastases and malignant ascites
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Figure 3 Scatterplot of exposure against dose. A: The scatterplot of TP3076 Cmax. B: The scatterplot of TP3076 AUC. C: The scatterplot of
TP3011 Cmax. D: The scatterplot of TP3011 AUC. E: The scatterplot of the sum of TP3076 and TP3011 Cmax. F: The scatterplot of the sum of
TP3076 and TP3011 AUC.
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resolution of her ascites although there was no radio-
logical change in the size of the metastatic deposits
whilst receiving 7 cycles of TP300. A further 5 patients
with metastatic adenocarcinoma of the colon or rectum
had stable disease as their best response, with 2 having
disease control for at least 4 cycles. All of these patients
had received irinotecan as part of their previous chemo-
therapy with the patients having the most durable dis-
ease control on TP300 having had a prior response to
irinotecan chemotherapy.
Topo-1 inhibitors remain clinically important in the
treatment of patients with cancer. TP300 has advantages
over other agents in this class in terms of tolerability and
the predictability of its principle toxicity, myelosuppres-
sion. Along with the apparent PK advantage of TP300
over irinotecan, biological activity evidenced by DNAstrand breaks, and preliminary evidence of clinical activ-
ity, these data warrant further evaluation of TP300.Conclusions
TP300 has biological activity as evidenced by DNA
strand break, with a clear relationship between exposure
and neutropenia, a toxicity profile superior to that of iri-
notecan, and preliminary evidence of clinical activity.
The 10 mg/m2 TP300 dose level was tolerable, but the
frequency of grade 4 neutropenia during cycle 1 led to
the recommended Phase II dose being 8 mg/m2 for cycle
1, increasing to 10 mg/m2 in subsequent cycles if toler-
ated. Exploratory studies combining TP300 with other
cytotoxics may be appropriate, especially where such
combinations have not been feasible with irinotecan due
to unacceptable gastrointestinal toxicity.
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Figure 5 The boxplot of AUC by genotype; AOX1(c3404 A>G), UGT1A1*28 or CYP2D6. A:The boxplot of TP3076 AUC by AOX1(c3404 A>G).
B:The boxplot of TP3011 AUC by AOX1(c3404 A>G). C:The boxplot of TP3076 AUC by UGT1A1 *28. D:The boxplot of TP3011 AUC by UGT1A1 *28.
E:The boxplot of TP3076 AUC by CYP genotype. F:The boxplot of TP3011 AUC by CYP genotype. E: Extensive metabolizer. I:Intermediate
metabolizer. P:Poor metabolizer.
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Figure 6 Mean tail moment of COMET assay result over time by
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Figure 4 Scatter plot of 1-Nadir/Pre-observation against AUC of
TP3076+TP3011. Circle: Subject without DLT Double circle: Subject
with DLT Solid line: Curve with sigmoid Emax model.
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